Clinical trials: Psoriasis Patients
Psoriasis Chronic
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs
The aim of this post-marketing observational study (PMOS) was to obtain further data on long-term safety, efficacy, and quality of life outcomes for adalimumab in routine clinical use in participants with moderate to severe…
- Trial name
- QUALITY (NCT01084668)
- Where
- 9 sites in Austria
- Volunteers
- 46 people
- Sponsor
- Abbott
Psoriatic Arthritis
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA…
- Trial name
- FUTURE 2 (NCT01752634)
- Testing
- Secukinumab (AIN457)
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis
The Psoriasis and a chronic dermatosis characterized by abnormal proliferation of cells epithelial, vessel dilation and inflammation locally, which presents erythematous-scaly lesions in various areas of the body, preferably in…
- Trial name
- halobetasol (NCT00715975)
- Testing
- halobetasol, clobetasol
- Where
- Brazil
- Volunteers
- 140 people
- Sponsor
- Azidus Brasil
Psoriasis, Plaque Psoriasis
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an…
- Trial name
- NCT05725057
- Testing
- AX-158
- Where
- 6 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Artax Biopharma Inc
Scalp Psoriasis
Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis
The purpose of this study is to compare the clinical efficacy of once daily treatment for 4 weeks with Xamiol® gel (calcipotriol plus betamethasone) with twice daily treatment for 4 weeks with Calcipotriol Scalp Solution in…
- Trial name
- NCT01195831
- Testing
- Xamiol® gel, Calcipotriol scalp solution
- Where
- 9 sites in China
- Volunteers
- 244 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
The main aim of the study is to evaluate the efficacy, safety and impact on the health-related quality of life (HRQoL) in participants with moderate-to-severe chronic plaque psoriasis who are treated with tildrakizumab 100…
- Trial name
- TRIBUTE (NCT04229836)
- Testing
- Tildrakizumab 100 mg Solution for Injection
- Where
- 39 sites in Italy, Spain
- Volunteers
- 178 people
- Sponsor
- Almirall, S.A.
Psoriasis Vulgaris
Body PSOriasis: Long-term Relapse CONTROL
This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow…
- Trial name
- PSO-CONTROL (NCT03402828)
- Testing
- Any topical drug treatment
- Where
- Russia
- Volunteers
- 764 people
- Sponsor
- LEO Pharma
Psoriasis
Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis
- Trial name
- NCT04930042
- Testing
- Stelara, AVT04
- Where
- 30 sites in Estonia, Georgia and 2 more
- Volunteers
- 581 people
- Sponsor
- Alvotech Swiss AG
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris
This study will compare efficacy and safety of once daily treatment of calcipotriol plus betamethasone dipropionate gel (LEO 80185) with tacalcitol ointment and LEO 80185 vehicle alone in subjects with psoriasis vulgaris.
- Trial name
- NCT00670241
- Testing
- calcipotriol and betamethasone (LEO 80185 gel), LEO 80185 vehicle, Tacalcitol ointment
- Where
- Canada
- Volunteers
- 458 people
- Sponsor
- LEO Pharma
Psoriasis
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712705
- Testing
- HPP737
- Where
- 50 sites in China
- Volunteers
- 515 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Psoriatic Arthritis
Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis
Study BCD-085-8/PATERA is a multicentre double-blind placebo-controlled Phase 3 study in patients with psoriatic arthritis (PsA).
- Trial name
- PATERA (NCT03598751)
- Testing
- BCD-085
- Where
- 3 sites in Belarus, Russia
- Volunteers
- 194 people
- Sponsor
- Biocad
Psoriasis
Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis.
- Trial name
- NCT00147329
- Testing
- MM-093
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merrimack Pharmaceuticals
Psoriasis
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18.
- Trial name
- TIPS (NCT00686686)
- Testing
- Infliximab
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Plaque Psoriasis
Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients
This study is to evaluate the efficacy and safety of M518101 and the dose relationship among two doses of M518101 and placebo in male and female plaque psoriasis patients.
- Trial name
- NCT01301157
- Testing
- M518101, Dovonex
- Where
- 32 sites in United States
- Volunteers
- 294 people
- Sponsor
- Maruho Co., Ltd.
Psoriasis
HPP737 in Adult Patients With Plaque Psoriasis
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712731
- Testing
- HPP737, Apremilast
- Where
- 60 sites in China
- Volunteers
- 607 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Plaque Psoriasis Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.
Phase III Efficacy and Safety Study of RSS0393 Ointment in Plaque Psoriasis.
- Trial name
- NCT07543224
- Testing
- RSS0393 ointment 0.03%
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Reistone Biopharma Company Limited
Psoriasis
A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis
The purpose of this study is to achieve a better understanding of clinical characteristics, treatment patterns and clinical outcomes of participants with moderate-to-severe plaque psoriasis (PsO) as well as their unmet medical…
- Trial name
- NCT05547490
- Where
- 2 sites in China
- Volunteers
- 3,506 people
- Sponsor
- Bristol-Myers Squibb
Mild-to-moderate Psoriasis Vulgaris
Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
The overall purpose of this study is to support the development of a DLX105 topical formulation for the indication mild to moderate psoriasis vulgaris.
- Trial name
- 2011-00500-15 (NCT01595997)
- Testing
- DLX105
- Where
- 2 sites in Austria, Germany
- Volunteers
- 20 people
- Sponsor
- Delenex Therapeutics AG
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Psoriasis, Arthritis, Psoriatic
Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.
- Trial name
- NCT00161655
- Testing
- Etanercept, Methotrexate
- Where
- 8 sites in Denmark, Finland and 2 more
- Volunteers
- 60 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer